Side Effects of Weight Loss Injections: What to Expect from GLP-1 Medications

Weight loss injections, including semaglutide, tirzepatide, and liraglutide, most often cause nausea, vomiting, diarrhea, constipation, stomach pain, and injection-site reactions. Serious but less common risks include pancreatitis, gallbladder disease, kidney problems from dehydration, hypoglycemia with some diabetes medicines, allergic reactions, and a boxed warning for thyroid C-cell tumors [1][2][3].

What counts as a weight loss injection?

Weight loss injections usually refer to injectable medicines used for chronic weight management, especially GLP-1 receptor agonists and GLP-1/GIP dual receptor agonists. These medicines affect appetite, fullness, stomach emptying, and blood sugar signaling, but they can also cause side effects in the gut and other organs [1][2][4].

Brand-name GLP-1s and dual agonists

Wegovy (semaglutide, a GLP-1 receptor agonist; also available as compounded semaglutide through some licensed 503A pharmacies) is FDA-approved for chronic weight management in eligible adults and adolescents and for reducing the risk of major adverse cardiovascular events in certain adults with cardiovascular disease and obesity or overweight [1]. Ozempic (semaglutide) is FDA-approved for type 2 diabetes and cardiovascular risk reduction in certain adults, not as a weight loss drug, though weight change has been observed in trials [4].

Zepbound (tirzepatide, a GLP-1/GIP dual receptor agonist; also available as compounded tirzepatide through some licensed 503A pharmacies) is FDA-approved for chronic weight management in eligible adults [2]. Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes, not as a weight loss drug [5]. Saxenda (liraglutide, a GLP-1 receptor agonist) is FDA-approved for chronic weight management in eligible adults and some adolescents [3].

Compounded semaglutide and compounded tirzepatide from 503A pharmacies

Compounded semaglutide and compounded tirzepatide are not FDA-approved products. They may be prepared by state-licensed 503A pharmacies for an individual patient when a licensed prescriber writes a prescription, and they do not go through FDA premarket review for safety, effectiveness, or quality the same way approved drugs do [10].

The FDA has warned patients and clinicians about dosing errors and adverse events reported with compounded injectable semaglutide products, especially when patients measure doses from vials or receive unclear instructions [11]. The FDA has also warned that some products marketed as semaglutide have used salt forms, such as semaglutide sodium or semaglutide acetate, which are different active ingredients from the semaglutide base used in FDA-approved products [12].

How these medications work in the body

GLP-1 receptor agonists mimic a gut hormone called glucagon-like peptide-1. They increase insulin release when glucose is high, reduce glucagon, slow stomach emptying, and act on brain pathways involved in appetite and fullness [1][4]. Tirzepatide also activates GIP receptors, which may affect insulin and energy-balance signaling, but it shares many digestive side effects with GLP-1 medicines [2][5].

What are the most common side effects?

The most common side effects of semaglutide, tirzepatide, and liraglutide are digestive. In FDA labeling, nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, and reflux are listed among common adverse reactions for these medicines [1][2][3].

Gastrointestinal: nausea, vomiting, diarrhea, constipation

Nausea is often the side effect people notice first. In the STEP 1 trial of semaglutide 2.4 mg once weekly, gastrointestinal events were more common with semaglutide than placebo, and most were mild to moderate and temporary; individual results and side effects vary [6].

Tirzepatide has a similar pattern. In the SURMOUNT-1 trial, tirzepatide at once-weekly doses of 5 mg, 10 mg, and 15 mg was linked with more gastrointestinal adverse events than placebo, mostly during dose escalation; individual results and side effects vary [7].

Injection-site reactions

Injection-site reactions can include redness, itching, swelling, bruising, or mild pain where the medicine enters the skin. These reactions are listed in FDA labeling for GLP-1 medicines, and a clinician should review symptoms that are severe, spreading, or linked with rash, trouble breathing, or facial swelling [1][2][3].

Fatigue, headache, and dizziness

Some people report fatigue, headache, dizziness, or feeling weak while taking weight loss injections. These symptoms can happen with lower food intake, dehydration, vomiting, diarrhea, or blood sugar changes, so persistent symptoms should be discussed with a clinician [1][2][3].

Appetite changes and early satiety

Feeling full sooner is an expected effect of this drug class, but eating too little can make nausea, dizziness, constipation, or fatigue worse. The goal is not to stop eating; it is to find a safe eating pattern that supports nutrition while side effects are monitored [1][2].

What serious side effects should I watch for?

Serious side effects are less common, but they matter. Pancreatitis, gallbladder disease, kidney injury from dehydration, hypoglycemia, severe allergic reactions, and thyroid C-cell tumor warnings appear in FDA labeling for one or more weight loss injections [1][2][3].

Pancreatitis

Pancreatitis means inflammation of the pancreas. FDA labels advise stopping the medication and seeking medical evaluation if pancreatitis is suspected, such as severe stomach pain that may move to the back and may come with vomiting [1][2][3].

Gallbladder disease and gallstones

Gallbladder problems, including cholelithiasis, which means gallstones, are listed in FDA labeling for semaglutide, tirzepatide, and liraglutide weight management products [1][2][3]. Rapid weight loss itself can also raise the risk of gallstones, so right-upper belly pain, fever, yellowing skin, or vomiting should be reviewed promptly [13].

Kidney problems from dehydration

Vomiting and diarrhea can lead to dehydration, which may worsen kidney function. FDA labels for GLP-1 medicines warn about acute kidney injury in some patients, often in the setting of severe gastrointestinal symptoms [1][2][4].

Hypoglycemia, especially with insulin or sulfonylureas

Hypoglycemia means low blood sugar. GLP-1 and GLP-1/GIP medicines can raise the risk of hypoglycemia when used with insulin or sulfonylureas, so clinicians often review diabetes medicines and glucose monitoring before and during treatment [1][2][5].

Boxed warning: thyroid C-cell tumors

Semaglutide, tirzepatide, and liraglutide products used for weight management carry an FDA boxed warning about thyroid C-cell tumors based on rodent findings. These medicines are contraindicated for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, also called MEN 2 [1][2][3].

Allergic reactions and anaphylaxis

Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 medicines. Symptoms such as trouble breathing, swelling of the face or throat, severe rash, or fainting need urgent medical care [1][2][3].

Are side effects different for semaglutide vs. tirzepatide?

Semaglutide and tirzepatide overlap a lot on side effects, but they are not the same medicine. Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GLP-1 and GIP receptors; both have FDA-approved weekly injection products and both use dose escalation in their labels [1][2].

How long do weight loss injection side effects last?

Side effects often occur during dose titration, which means the dose is raised over time according to the FDA label or a clinician’s plan. In trials of semaglutide and tirzepatide, gastrointestinal side effects were commonly reported during escalation and were often mild to moderate, but some people stopped treatment because of adverse events [6][7].

Typical timeline during dose escalation

FDA labeling uses gradual escalation schedules to help reduce gastrointestinal side effects. For example, the Wegovy label starts at 0.25 mg once weekly for 4 weeks before stepwise increases toward 2.4 mg, while the Zepbound label starts at 2.5 mg once weekly for 4 weeks before increases toward labeled maintenance doses [1][2].

When side effects usually fade

Many digestive symptoms improve as the body adjusts, but not everyone follows the same pattern. Symptoms may return when the dose is increased, and some people need a slower plan, a pause in escalation, or a different treatment after clinician review [1][2][6][7].

When to call your clinician

Call a clinician if nausea, vomiting, diarrhea, or constipation is severe, lasts more than a few days, or prevents normal eating and drinking. Seek urgent care for severe stomach pain, signs of dehydration, fainting, low blood sugar symptoms, yellowing skin, trouble breathing, or swelling of the face or throat [1][2][3].

How can I reduce or manage side effects?

Side-effect management should be personalized. Slow titration, dose adjustments, hydration, meal changes, fiber, and injection-site rotation may help some people, but persistent or severe symptoms need medical review [1][2][14].

Slow titration and dose adjustments

FDA labels for semaglutide, tirzepatide, and liraglutide use stepwise dose escalation rather than starting at the full maintenance dose [1][2][3]. If side effects are hard to tolerate, the right next step is a clinician conversation, not changing the dose on your own.

Diet strategies for nausea and reflux

Smaller meals, slower eating, and limiting high-fat meals may reduce nausea or reflux for some people taking GLP-1 medicines, because these drugs slow stomach emptying [1][4][14]. A clinician or dietitian can help if nausea leads to very low intake, weakness, or poor nutrition.

Hydration and fiber for GI symptoms

Hydration matters because vomiting and diarrhea can increase dehydration risk, and dehydration can contribute to kidney problems [1][2]. Fiber may help constipation, but sudden large increases can worsen bloating, so people with severe constipation, gastroparesis symptoms, or abdominal pain should ask a clinician before making big changes [14].

Injection technique and site rotation

FDA labels describe subcutaneous injection, meaning medicine is injected under the skin, and advise using approved injection sites according to product instructions [1][2][3]. Rotating injection sites may reduce local irritation, and any spreading redness, warmth, drainage, or severe swelling should be checked.

Who should not use weight loss injections?

Some people should not use these medicines, and others need extra monitoring. Medullary thyroid carcinoma, MEN 2, pregnancy, breastfeeding, pancreatitis history, severe gastrointestinal disease, and certain diabetes medicines are key issues for clinician review [1][2][3].

Personal or family history of medullary thyroid cancer or MEN 2

Wegovy, Zepbound, and Saxenda are contraindicated in people with a personal or family history of medullary thyroid carcinoma or in people with MEN 2. This is because of the boxed warning for thyroid C-cell tumors in their FDA labels [1][2][3].

History of pancreatitis

FDA labels warn about pancreatitis, and some labels state the medication has not been studied in patients with a history of pancreatitis or should be used with caution depending on the product [1][2][3]. A prior pancreatitis history should be reviewed before prescribing.

Pregnancy and breastfeeding

Weight loss offers no benefit during pregnancy and may harm a fetus. FDA labeling advises discontinuing weight management GLP-1 products when pregnancy is recognized, and patients who are pregnant, planning pregnancy, or breastfeeding should discuss options with a clinician [1][2][3].

Other contraindications and cautions

People with severe gastroparesis symptoms, serious allergic reactions to a product ingredient, kidney disease, gallbladder disease, diabetes treated with insulin or sulfonylureas, or a history of eating disorders may need different monitoring or may not be candidates. These issues are part of a standard prescribing review [1][2][3][14].

Are compounded weight loss injections riskier?

Compounded weight loss injections are not FDA-approved products, so their risk profile depends on the prescription, pharmacy quality systems, ingredient sourcing, concentration, labeling, and patient instructions. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are dispensed [10].

How 503A compounding pharmacies are regulated

A 503A compounding pharmacy is a state-licensed pharmacy that prepares a medication for an individual patient based on a valid prescription. These pharmacies must follow federal conditions for 503A compounding, but compounded drugs are still different from FDA-approved brand-name products [10].

Active ingredient vs. salt forms — what to ask

The FDA has stated that semaglutide sodium and semaglutide acetate are salt forms and are different from the semaglutide base used in FDA-approved medicines. Patients should ask what active ingredient is being used, whether the pharmacy is licensed, and whether the prescription and instructions are clear [12].

Why clinician oversight matters

Clinician oversight matters because side effects may require a change in the treatment plan, review of other medicines, lab monitoring, or urgent care. FDA has received reports of dosing errors with compounded semaglutide, including errors related to measuring doses from vials and confusing units, milligrams, and milliliters [11].

How do I get a weight loss injection with clinical oversight?

A safe path starts with a medical review, not a shopping cart. A licensed clinician should confirm the diagnosis and indication, check contraindications, review medications, explain FDA-approved and compounded options, and make a follow-up plan for side effects and dose changes [1][2][10].

You can seek care through an in-person clinician, an obesity-medicine specialist, or a licensed telehealth provider. Chia is one option for clinician-reviewed access to compounded GLP-1 medications through licensed 503A pharmacy partners, when a prescription is appropriate after evaluation.

Frequently asked questions

Keep reading

Weight Loss Medication

Peptides for Weight Loss: Side Effects, Risks, and What to Watch For

GLP-1 Weight Loss

How to Get Weight-Loss Injections Online: A Step-by-Step Guide

GLP-1 Medications

GLP-1 Side Effects: What to Expect and How to Manage Them